Collectively, these findings emphasize the central immunoregulatory function of TGFβ1+ Tregs in CRC progression, highlighting them as potential therapeutic targets for modulating the tumor microenvironment and restoring antitumor immunity. This evidence concerns the gene TGFB1 and colorectal carcinoma.